{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:42:58Z","timestamp":1773153778528,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA31946"],"award-info":[{"award-number":["CA31946"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA33601"],"award-info":[{"award-number":["CA33601"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.leukres.2010.07.017","type":"journal-article","created":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T04:59:22Z","timestamp":1280984362000},"page":"329-333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902"],"prefix":"10.1016","volume":"35","author":[{"given":"Richard M.","family":"Stone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Moser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Schulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan E.","family":"Kolitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilene","family":"Galinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hurd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2010.07.017_bib0005","first-page":"1003","article-title":"Optimizing therapy for acute myeloid leukemia","volume":"6","author":"Kohrt","year":"2008","journal-title":"JNCCN"},{"key":"10.1016\/j.leukres.2010.07.017_bib0010","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1634\/theoncologist.2008-0224","article-title":"Acute myelogenous leukemia in older adults","volume":"14","author":"Klepin","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2010.07.017_bib0015","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/MOH.0b013e3282f463d2","article-title":"Novel strategies for relapsed and refractory acute myeloid leukemia","volume":"15","author":"Mato","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.leukres.2010.07.017_bib0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.beha.2007.11.013","article-title":"Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML)","volume":"21","author":"Appelbaum","year":"2008","journal-title":"Bailliere's Best Pract Clin Haematol"},{"key":"10.1016\/j.leukres.2010.07.017_bib0025","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.seminhematol.2007.08.002","article-title":"Acute myeloid leukemia and the position of autologous stem cell transplantation","volume":"44","author":"Breems","year":"2007","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2010.07.017_bib0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/bmt.2009.36","article-title":"Auto-SCT for AML in second remission: CALGB study 9620","volume":"44","author":"Linker","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2010.07.017_bib0035","first-page":"253","article-title":"High dose cytarabine: a review","volume":"2","author":"Bolwell","year":"1988","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.07.017_bib0040","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2004-05-1933","article-title":"Results of a phase 1\u20132 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias","volume":"105","author":"Faderl","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.07.017_bib0045","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1200\/JCO.1995.13.3.560","article-title":"Improved survival for patients with acute myelogenous leukemia","volume":"13","author":"Mitus","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.07.017_bib0050","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.07.017_bib0055","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1517\/14712598.1.5.893","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"1","author":"Sievers","year":"2001","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.leukres.2010.07.017_bib0060","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1200\/JCO.1988.6.2.213","article-title":"Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia \u2013 an active and well-tolerated regimen","volume":"6","author":"Ho","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.07.017_bib0065","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1600-0609.2007.00988.x","volume":"80","author":"Wierzbowska","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2010.07.017_bib0070","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/ajh.21545","article-title":"Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF","volume":"84","author":"Martin","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2010.07.017_bib0075","doi-asserted-by":"crossref","first-page":"8403","DOI":"10.1158\/1078-0432.CCR-05-1201","article-title":"Phase I and pharmacokinetic study of flavopiridol followed by 1-\u03b2-d-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory acute leukemias","volume":"11","author":"Karp","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2010.07.017_bib0080","doi-asserted-by":"crossref","first-page":"6732-9","DOI":"10.1158\/1078-0432.CCR-09-0842","article-title":"A phase I study of the mammalian target of rapamycin inhibits sirolimus and MEC chemotherapy in relapsed and refractory myelogenous leukemia","volume":"15","author":"Perl","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2010.07.017_bib0085","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.1988.6.2.232","article-title":"The characteristics and outcome of patients with late relapse acute myelogenous leukemia","volume":"6","author":"Kantarjian","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.07.017_bib0090","unstructured":"Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7:1490\u20136 [erratum appears in Clin Cancer Res 2002;8(January (1)):300]."},{"key":"10.1016\/j.leukres.2010.07.017_bib0095","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate","volume":"93","author":"Sievers","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.07.017_bib0100","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.07.017_bib0105","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/cncr.11791","article-title":"Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia","volume":"98","author":"Giles","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.07.017_bib0110","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.07.017_bib0115","unstructured":"DeAngelo D, Stone R, Durrant S, Liu D, Baccarani M, Schiffer CA, et al. Gemtuzumab ozogamicin (Mylotarg\u00ae) in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: two age-specific phase II trials. Blood 2003;102:146a [abstract 502]."},{"key":"10.1016\/j.leukres.2010.07.017_bib0120","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1182\/blood-2003-05-1620","article-title":"A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia","volume":"102","author":"Kell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.07.017_bib0125","doi-asserted-by":"crossref","unstructured":"Burnett AK, Kell WJ, Goldstone AH, Milligan D, Hunter A, Prentice AG, et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML 15 Trial. Blood 2006;108:8a [abstract 13].","DOI":"10.1182\/blood.V108.11.13.13"},{"key":"10.1016\/j.leukres.2010.07.017_bib0130","doi-asserted-by":"crossref","unstructured":"Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevill TJ, Stenke L, et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 2009;114:327a [abstract 790].","DOI":"10.1182\/blood.V114.22.790.790"},{"key":"10.1016\/j.leukres.2010.07.017_bib0135","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.07.017_bib0140","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1200\/JCO.2007.15.9764","article-title":"Long-term disease-free survival after gemtuzumab, intermediate dose cytarabine, and mitoxantrone in patients with CD33+primary resistant or relapsed acute myeloid leukemia","volume":"26","author":"Chevalier","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610003607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610003607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:57:14Z","timestamp":1758934634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212610003607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0145212610003607"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2010.07.017","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2010.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}